Efficacy Results of a SURPASS open-label, phase III trial, published in 2021, demonstrated tirzepatides superior glycaemic efficacy and weight reduction compared with existing GLP-1 receptor agonists, including semaglutide 6
Comparison of kidney transcriptomic profiles of early and advanced diabetic nephropathy reveals potential new mechanisms for disease progression
Some individuals might find weight reduction unsettling or experience concerns about their changing appearance, though there is limited evidence directly linking this to anxiety symptoms
Tolerability (veterinary): Generally well tolerated in veterinary studies, with occasional mild injection-site reactions
For ongoing monitoring after the acute period, arrange a follow-up appointment with your GP or diabetes specialist nurse within a few days to review your blood glucose control, assess for any delayed complications, and discuss strategies to prevent future dosing errors
T**Y Great Results I have tried several probiotics and could never find the right one until these